Serum-based tracking of de novo initiated liver cancer progression reveals early immunoregulation and response to therapy.

ABSTRACT:

Background & aims

Liver inflammatory diseases associated with cancer promoting somatic oncogene mutations are increasing in frequency. Preclinical cancer models that allow for the study of early tumor progression are often protracted, which limits the experimental study parameters due to time and expense. Here we report a robust inexpensive approach using Sleeping Beauty transposition (SBT) delivery of oncogenes along with Gaussia Luciferase expression vector GLuc, to assess de novo liver tumor progression, as well as the detection of innate immune responses or responses induced by therapeutic intervention.

Methods

Tracking de novo liver tumor progression with GLuc was demonstrated in models of hepatocellular carcinoma (HCC) or adenoma (HCA) initiated by hydrodynamic deliver

SUBMITTER: Subleski JJ 

PROVIDER: S-EPMC4615530 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature